New biopsy technique aims to unlock prostate Cancer's secrets
NCT ID NCT02313623
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study at Yale University enrolled 600 men with prostate cancer to test a new biopsy method that combines MRI and ultrasound images. The goal was to collect extra tissue samples for detailed single-cell analysis, looking at proteins and other markers to better predict how the cancer will behave. The main focus was on whether prostate cancer cells could be successfully grown in the lab from these samples.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to better ways to predict how prostate cancer will progress, helping doctors choose the right treatment for each patient.
- What could go wrong
- This is an early-stage research study focused on collecting and analyzing cells, not testing a new treatment. The findings may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Jul 2013
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with scheduled Artemis fusion biopsy will be recruited into this study.
- Ages
-
18 to 80 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Only subjects that have scheduled Artemis prostate biopsy with defined regions of interest will be included in this study Exclusion Criteria: * Any subjects that are unable to provide informed consent will be excluded
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?